Repurposed drugs: second time lucky

The drug discovery and development path for a new chemical entity (NCE) can take ten to 15 years and cost between $1 billion and $2 billion. ‘Repurposing’ is the practice of finding novel therapeutic indications for existing drugs. Typically the selected drug will have already been shown to be safe in patients, thereby significantly reducing the time it takes to bring the drug to market.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

UK patent office adopts EPO standards for AI inventions

9 April 2026 In light of Emotional Perception AI, the UKIPO has rewritten the rules for “mixed inventions". Matt Jefferies and Eric McNeil of Marks & Clerk explore what this pivot means for applicants protecting their AI technology.

Europe

European patent offices raise fees

2 April 2026 Two of Europe’s most important IP offices have implemented fee increases this month, with some long-standing UK charges, dating back to the late 1990s, finally seeing a rise.

Europe

UPC refuses early knockout in Illumina–Element dispute

2 April 2026 A Lisbon judge rejects a bid to strike out the case over a drafting issue, offering insight into the court’s high bar for early dismissal.

More features

UK patent office adopts EPO standards for AI inventions

Gilead to pay up to $5bn for antibody-drug conjugates push

Closing the women's health gap offers ‘benefits for all’

European patent offices raise fees

UPC refuses early knockout in Illumina–Element dispute

IndiaMart v CDSCO: A test of intermediary liability

UPC appeals court upholds Abbott injunction in glucose monitoring patent dispute

Novartis bets $2bn on biologics as Xolair patents fade

Repurposed drugs: second time lucky

More on this story

Editor's picks

Editor's picks

More features